Universität zu Köln

Kakkassery, Vinodh, Emmert, Steffen, Adamietz, Irenaeus A., Kovacs, Gyoergy, Juenemann, Anselm M., Otte, Caroline, Zimbelmann, Michael, Brosig, Anton, Grisanti, Salvatore and Heindl, Ludwig M. (2020). Alternative treatment options for periorbital basal cell carcinoma. Ophthalmologe, 117 (2). S. 113 - 124. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0423

Full text not available from this repository.

Abstract

Background Latest developments as well as established procedures offer alternative treatment approaches to basal cell carcinoma (BCC) when micrographically controlled surgical removal is not a valid option. Objective Alternative treatment options for periorbital BCC are presented. Methods A literature search was carried out and a structured display and analysis of the results are given. Results Micrographically controlled surgical removal represents the gold standard in treatment of BCC. When for various reasons surgical removal is not a valid option, other procedures are required. The alternative treatment options can be divided into three main groups: treatment options for locally advanced or metastasized BCC, topical approaches for small and superficial BCC and prophylactic measures. While radiotherapy and systemic therapy are suitable for locally advanced BCC and are discussed in a tumor board, small and superficial BCC can be treated by topical medication. In cases of a previous BCC history, a prophylactic treatment can be considered. Combinations of systemic treatment and also neoadjuvant or adjuvant approaches before and after surgery are promising options for a successful outcome, which can further improve the standard treatment for locally advanced BCC. Conclusion Alternative treatment options for periocular BCC are available; however, the use is only indicated when microscopically controlled excision with subsequent oculoplastic reconstruction is not possible. According to the national guidelines a prior presentation to a suitable tumor board is practically compulsory.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kakkassery, Vinodh UNSPECIFIED UNSPECIFIED UNSPECIFIED Emmert, Steffen UNSPECIFIED UNSPECIFIED UNSPECIFIED Adamietz, Irenaeus A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kovacs, Gyoergy UNSPECIFIED UNSPECIFIED UNSPECIFIED Juenemann, Anselm M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Otte, Caroline UNSPECIFIED UNSPECIFIED UNSPECIFIED Zimbelmann, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Brosig, Anton UNSPECIFIED UNSPECIFIED UNSPECIFIED Grisanti, Salvatore UNSPECIFIED UNSPECIFIED UNSPECIFIED Heindl, Ludwig M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-347328
DOI:	10.1007/s00347-019-01021-4
Journal or Publication Title:	Ophthalmologe
Volume:	117
Number:	2
Page Range:	S. 113 - 124
Date:	2020
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0423
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HEDGEHOG PATHWAY INHIBITION; IMIQUIMOD 5-PERCENT CREAM; NIVOLUMAB PLUS IPILIMUMAB; SKIN-CANCER; OPEN-LABEL; ELECTRONIC BRACHYTHERAPY; CUTANEOUS METASTASES; NORMAL TISSUE; HIGH-RISK; PHASE-II Multiple languages Ophthalmology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/34732